A Phase 2, Open Label, Multicentre, Sequential Dose Finding Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Multiple Doses of Polysialylated Erythropoietin [PSA-EPO; PSA-epoetin alfa; ErepoXen (registered trade name)] Administered Subcutaneously in Chronic Kidney Disease (CKD) Subjects Not on Dialysis and Not Receiving Erythropoiesis Stimulating Agents (PSA-EPO-06)
100 Clinical Results associated with Xenetic Biosciences (UK) Ltd.
0 Patents (Medical) associated with Xenetic Biosciences (UK) Ltd.
100 Deals associated with Xenetic Biosciences (UK) Ltd.
100 Translational Medicine associated with Xenetic Biosciences (UK) Ltd.